semaglutide news october 2025 versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial GLP-1 Pipeline Update: May 2025

HA nanohybrid NDDSs section summarizes the application of HA as an increase in the targeting ability or increased biocompatibility of other NDDSs, and the introduction of HA has dramatically broadened the choice of nano drugs in the treatment of breast cancer

IV is the most direct delivery

Currently, formulary-exclusions from branded manufacturers have relegated generics of exenatide and of liraglutide (first-generation GLP-1s which have already gone generic) to the overlooked and unknown in spite of years of proven efficacy

All guidance on administration, injection sites, and storage must therefore come from the clinical trial protocol, the Investigational Medicinal Product (IMP) label, and the instructions for use (IFU) supplied with your specific device

Lages M, Barros R, Moreira P, Guarino MP